Measurement of plasma levels of both KYNA and QA in mice treated with KMO inhibitors.
Mice were treated with two selective KMO inhibitors – Ro-618048 & UPF648 – at two different doses each. Plasma samples were collected before treatment and at 1h30 and 6h post-treatment. KYNA and QA levels were then quantified by mean of ELISA (IS-I-0200 and IS-I-0100). As depicted above, blockade of KMO time- and dose-dependently favors the degradation of Kynurenine into KYNA. Interestingly, no major effect is observed on QA level thus suggesting compensatory mechanism to maintain stable circulating QA level.
Kynureninic Acid/Quinolinic Acid ELISA pack (KYNA/QA ELISA pack)Ref: ISE-0102
Through the degradation of L-Tryptophan, the Kynurenine pathway (KP) generates a series of catabolites collectively known as Kynurenines, which can exert immunomodulatory and/or neuroactive properties. Known to respectively harbor neuroprotective and neurotoxic functions, Kynurenic (KYNA) and Quinolinic (QA) acids are found to be dysregulated in several neuroinflammatory disorders including Parkinson and Alzheimer disease but also Amyotrophic Lateral Sclerosis and Multiple Sclerosis.
The two kits included in the pack are ready to use, optimized for the quantitation of Kynurenic Acid (KYNA) and Quinolinic Acid (QA) within serum and plasma samples. These easy-to-use competitive assays are well-suited for both small and large series of samples. Working with a 25-50µL sample volume, these assays enable pre-clinical and clinical sample testings.
|Kit capacity||2 x 96 tests|
LoD KYNA: 0.53 ng/ml
LoD QA: 6 ng/ml
KYNA: 1.40 - 74 ng/ml
QA: 25 - 2000 ng/ml
|Species reactivity||Reacts with all species|
Offer valid until July 10, 2020
Shipping info :
(for 1 kit)
|81.00€ , 5 days|
|Product information||Key steps||References||Technical support||Reviews|
|Sample collection & storage||
Serum: Do not use lipemic, haemolytic samples, as well as samples containing precipitates or fibrin strands. Store samples at 2-8°C for up to 48h or -20°C for longer period (up to 6 months).
KYNA: Sample derivatization (90 min)
QA: Sample acylation (120 min)
|ELISA||Antisera overnight incubation, revelation and read steps (1h).|
|Detailed protocol||Instructions for use - KYNA kit, Instructions for use - QA kit|
Selected articles on Kynurenic acid:
- Pedraz-Petrozzi et al. Effects of inflammation on the kynurenine pathway in schizophrenia - a systematic review. J Neuroinflammation. 2020
- Achtyes et al. Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression. Brain Behav Immun. 2020
- Walczak et al. Kynurenic acid and cancer: facts and controversies. Cell Mol Life Sci. 2019
- Lim et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep. 2017
- Plitman et al. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2017
- Wirthgen et al. Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions. Front Immunol. 2017
Selected articles on Quinolinic acid:
- Fertan et al. Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice. Front Pharmacol. 2019 Sep;24
- Pierozan et al. Synergistic Toxicity of the Neurometabolites Quinolinic Acid and Homocysteine in Cortical Neurons and Astrocytes: Implications in Alzheimer's Disease. Neurotox Res. 2018 Jul;34
- Hernandez-Martinez et al. Quinolinic acid induces neuritogenesis in SH-SY5Y neuroblastoma cells independently of NMDA receptor activation. Eur J Neurosci. 2017 Mar;45
- Sundaram et al. Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies. J Neuroinflammation. 2014 Dec 13
Just ask us. We provide technical support within 24h.